Diagnosis, clinic and treatment of adynamic bone disease with/without osteopenia/osteoporosis;Diagnostik, klinik und behandlung der adynamen knochenerkrankung mit/ohne osteopenie/osteoporose

Nieren- und Hochdruckkrankheiten

Volumn 36, Issue 8, 2007, Pages 310-332

  Humpfner A ^a,b  

^a Nephrologische Gemeinschaftspraxis Mit Dialysezentrum   (Germany)

^b Nephrologische Schwerpunktpraxis Mit Dialysezentrum   (Germany)

Author keywords

Adynamic bone disease (ABD); Aluminum toxicity; Cardiovascular mortality; Hypoparathyroidism; Prevention therapy; PTH resistance; Renal osteoporosis; Risk factors; sHPT oversuppression; Stress fractures

Indexed keywords

CALCIUM; VITAMIN D;

BONE DISEASE; CALCIUM INTAKE; CALCIUM TRANSPORT; CONFERENCE PAPER; HEMODIALYSIS PATIENT; HUMAN; HYPOPARATHYROIDISM; LIFESTYLE; MORBIDITY; MORTALITY; OSSIFICATION; OSTEOPOROSIS; PREVENTION AND CONTROL; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 34548507525     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: 10.5414/nhp36310     Document Type: Conference Paper

References (63)

1. Armstrong A., J. Beer, K. Noonan, J. Cunningham: Reduced calcium dialysate in CAPD patients: efficacy and limitations. Nephrol. Dial. Transplant. 12, 1223-1228 (1997).
2. Avram M.M., N. Mittman, M.M. Myint, P. Fein: Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am. J. Kidney Dis. 38, 1351-1357 (2001).
3. Bischoff-Ferrari H.K.: Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am. J. Clin. Nutr. 84, 18-28 (2006).
4. Block G.A., T.E. Hulbert-Shearon, N.W. Levin, F.K. Port: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 31, 607-617 (1998).
5. Block G.A., P. Klassen., M. Danese: Association between proposed NKF-K/DOQI-bone metabolism and disease guidelines and mortality risk in hemodialysis patients. J. Am. Soc. Nephrol. 14, 474A (2003).
6. Block J.P., S. Klassen J.M. Lazarus, N. Ofsthun, E.G. Lowrie, G.M. Chertow: Mineral metabolism, mortality and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15, 2208-2218 (2004).
7. Braun J., M.W. Oldendorf, W. Moshage, F. Heidler, E. Zeitler, F.C. Luft: Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients. Am. J. Kidney Dis. 27, 394-401 (1996).
8. Cannata-Andia J.B., C.G. Alonso: Vitamin D deficiency: a neglected aspect of disturbed calcium metabolism in renal failure. NDT 17, 1875-1878 (2002).
9. Coco M., H. Rush: Increased incidence of hip fracture in dialysis patients with low serum parathyroid hormone. Am. J. Kidney Dis. 33, 1115-1121 (2000).
10. Coen G., P. Ballanti, E. Bonucci, S. Calabria, M. Centorrino, V. Fassino et al.: Bone markers in the diagnosis of low-turnover osteodystrophy in haemodialysis patients. Nephrol. Dial. Transplant. 13, 2294-2302 (1998).
11. Coen D.: Adynamic bone disease: an update and overview. J. Nephrol. 18, 117-122 (2005).
12. Couttenye M.M., P. dHaese, W.M. Verschoren, G.J. Behets, I. Schoten, M.E. De Broe: Low bone turnover in patients with renal failure. Kidney Int. 56 (Suppl). 70-76 (1999).
13. Dachverband deutschsprachiger wissenschaftlicher Fachgesellschaften für Osteologie (DVO): Evidenzbasierte Konsensus-Leitlinien zur Osteoporose bei Frauen ab der Menopause und Männem ab dem 60. Lebensjahr. www.lutherhaus-essen.de/osteo/leitlinien-dvo/
14. DeBroe M.E., P.C. DHaese, F.L. van de Vyver, L.V. Lamberts: Aluminiuminduzierte Osteopathie bei Patienten mit chronischer Niereninsuffizienz. Nieren-Hochdruckkrkh. 7, 311-316 (1991).
15. Delling G., M. Werner, H. Ritzel, W. Schulz: Trabekuläre Mikroarchitektur und Pathohistologie bei renaler Low-turnover-Osteopathie Typ IIa mit Osteopenia Nieren-Hochdruckkrkh. 28, 386-393 (1999).
16. Deuber H.J., M. Hammerschmidt, U. Bunnemann: Wirksamkeit eines neuen kalzium- und magnesiumhaltigen Phosphatbinders bei Hämodialyse- patienten. Nieren-Hochdruckkrkh. 30, 416 (2001).
17. Deuber H.J.: Kombinierter Einsatz von Kalziumacetat und Magnesiumcarbonat als orale Phosphatbinder. Nieren-Hochdruckkrkh. 33, 403-408 (2004).
18. DHaese P.C., G.B. Spasovski, A. Sikole, A. Hutchison, T.J. Freemont, S. Sulkova et al.: A multicentre study on the effects of lanthanum carbonate (Fosrenol®) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int. 63 (Suppl. 85), 73-78 (2003).
19. Eknoyan, G., A. Levin, N. Levin for the National Kidney Foundation: K/DOQI-Guidelines: Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. AJKD 42 (Suppl. 3), S1-S201 (2003). Deutsche Übersetzung: www.dialyse.de/wissenschaft/k-doqi- guidelines-knochenstoffwechsel-und-renale-osteopathie-bei-chronischer- nierenerkrankung
20. Fournier A., R. Oprosiu, S. Said: Invasive versus noninvasive diagnosis of renal bone disease. Curr. Opin. Nephrol. Hypertens. 6, 333-348 (1997).
21. Fournier A., R. Oprosiu, S. Ghitu: Adynamic bone disease in patients on maintainance dialysis: clinical relevance, noninvasive diagnosis and preventive treatment. Nieren-Hochdruckkrkh. 28, 394-401 (1999).
22. Friedmann P.A., W.G. Goodmann: PTH(1-84)/PTH(7-84): a balance of power. Am. J. Physiol. Ren. Physiol. 290, 975-984 (2005).
23. 4 product and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J. Am. Soc. Nephrol. 12, 2131-2138 (2001).
24. Gerakis A., A.J. Hutchison, T. Apostolou, A.J. Freemont, A. Billis: Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on hemodialysis. Nephrol. Dial. Transplant. 11, 2430-2438 (1996).
25. Goodman W.G., J.A. Ramirez, T.R. Belin, Y. Chon, B. Gales, G.V. Segre, I.B. Salusky: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 46, 1160-1166 (1994).
26. Guh J.H., H.C. Chen, H.Y. Chuang, S.H. Huang, L.C. Chien, Y.H. Lai: Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am. J. Kidney Dis. 39, 1245-1254 (2002).
27. Herez G., Y. Pei, C. Greenwood, A. Manuel, C. Saiphoo, W.G. Goodman, G.V. Segre, S. Fenton, D.J. Sherrard: Aplastic osteodystrophy without aluminum. The role of "suppressed" parathyroid function". Kidney Int. 43, 860-866 (1993).
28. Hümpfner A., S. Hummel, W. Schulz: Diagnostic und therapeutical approaches to aluminum overload in dialysed patients - representative study by questionnaire in West German dialysis units in 1989 - 1990. Nephrol. Dial Transplant. Suppl. 1, 51-54 (1993).
29. Hümpfner A.: Die adynamische Knochenerkrankung (ABD) unter Aluminiumeinfluss bei chronischer Nicreninsuffizienz und Dialyse (HD, CAPD). Das Risiko der unterschätzten subklinischen Aluminiumtoxizität bei herabgesetzter Toxizitätsschwelleheute. Nieren-Hochdruckkrkh. 25, 50-71 (1996).
30. Hümpfner A.: Renale Osteopathie und dialyseas-soziierte Amyloidose. In: G. Schönweiß: Dialysefibel 3, Band 1. Abakiss-Verlag, Nüdlingen 2006, 254-403.
31. 3 and radiology in end-stage renal disease. Kidney Int. 44, 19-29 (1993).
32. Hutchison A.J., B. Maes, J. Vanwalleghem et al: Efficacy, tolerability and safety of lanthanum carbonate in hyperphosphatemia: a 6-month randomized, comparative trial versus calcium carbonate. Nephron. Clin. Pract. 100, c8-c19 (2005).
33. 2+". Fresenius Medical Care, Bad Homburg 2002.
34. Jehle D.R., F. Keller, P.M. Jehle: Pathophysiologie und Therapie der renalen Osteopathie: Neuer Wein in alten Schläuchen. Osteologie forum 3, 24-33 (1997).
35. Ketteler M., P. Bongartz, R. Westenfeld, J. Wildberger, A. Mahnken, R. Böhm et al.: Association of low fetuin A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross sectional study. Lancet 361, 827-833 (2003).
36. Ketteler M., V. Brandenburg, W. Jahnen-Dechent, R. Westenfeld, J. Floege: Do not be misguided by guidelines: the calcium x phosphate product can be a Trojan horse. Nephrol. Dial. Transplant. 20, 673-677 (2005).
37. Ketteler M., R. Westenfeld, G. Schlieper V. Brandenburg: Pathogenesis of vascular calcification in dialysis patients. Clin. Exp. Nephrol. 9, 265-270 (2005).
38. Kurz P., M.C. Monier-Faugere, B. Bognar, E. Werner, P. Roth, J. Vlachojannis, H.H. Malluche: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 46, 855-861 (1994).
39. Lee R.: Pharmacoeconomics: hip fracture in dialysis patients. Orthop. Technol. Rev. 4, (2002). www.orthopedictechreview.com
40. London G.M., C. Marty, S.J. Marchais, A.P. Guerin, F. Metivier, M.C. de Vernejoul: Arterial calcifications and bone histomophometry in end-stage renal disease. J. Am. Soc. Nephrol. 15, 1943-1951 (2004).
41. Lorenzo V., M. Martin, M. Rufina, A.J. Ba Sci, A.M. Malo, E. Sanchez, D. Hernandez, M. Rodriguez, A. Torres: Adynamic bone: mechanisms in the elderly end-stage renal disease patients? 2nd International Congress of Nephrology in Internet (2001). www.uninet.edu/cin2001
42. Lund R.J., M.R. Davies, A.J. Brown, K.A. Hruska: Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. JASN 15, 359-369 (2004).
43. Malluche H.H., M.C. Monier-Faugere: Risk of adynamic bone disease in dialyzed patients. Kidney Int. 42 (Suppl. 38), 62-67 (1992).
44. Malluche H.H., H. Mawad, D. Trueda, M.C. Monier-Faugere: Parathyroid hormone assays: evolution and revolution in the care of dialysis patients. Clin. Nephrol. 59, 313-318 (2003).
45. Malluche H.H.: Renale Osteodystrophie und vaskuläre Kalzifizierung. Med. Review 13, 15-16 (2006).
46. Moe S., T. Drüeke, J. Cunningham, W. Goodman, K. Martin, K. Olgaard, S. Ott, S. Sprague, N. Lameire, G. Eknoyan: Definition, evaluation and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 69, 1945-1953 (2006).
47. Marco M.P., L. Craver, A. Betriu, M. Belart, J. Fibla, E. Fernandez: Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int. 63 (Suppl. 85), 111-114 (2003).
48. Nikura K., T. Akizawa, Y. Satoh: Relative hypoparathyroidism in hemodialysis patients. Miner. Electrolyte Metab. 21, 101-103 (1995).
49. Pfeifer M., H.W. Minne: Prävention von Stürzen und Frakturen bei älteren Menschen: Vitamin-D-und Kalziumsupplementation sind wirksam. Dtsch. Ärztebl. 103, 116-117 (2006).
50. Reichel H., C. Benzing: Pathogenese der adynamen Osteopathie bei chronischer Niereninsuffizienz. Nieren-Hochdruckkrkh. 28, 379-385 (1999).
51. Salusky I.B., W.G. Goodman: Adynamic renal osteodystrophy: Is there a problem? J. Am. Soc. Nephrol. 12, 198-205 (2001).
52. Scantibodies Clinical Laboratory: PTH Accuratio TM-1-84 PTH/7-84 PTH Ratio. www.scltesting.com (2006).
53. 3 sowie von Knochen-An- und Abbauparametern zur Beurteilung des Ausmaßes des sekundären Hyperparathyreoidismus (sHPT) bei chronischer Niereninsuffizienz (CNI). 30. Nephrologisches Seminar Bamberg, 30.06 - 01.07.2006, Abstract-Band, Seite 32-33 (2006).
54. Schulz W., H.J.Deuber, K. Schulten, G. Werthmann, G. Delling: Low-turnover-Osteopathie (Osteopenie) bei Patienten mit chronischer Hämodialyse. Nieren-Hochdruckkrkh. 24, 368-372 (1995).
55. Schulz W., G. Delling: Adyname Knochenerkrankung (Low-tumover-Osteopathie Osteopenie) bei chronischer Niereninsuffizienz und Dialyse. Nieren-Hochdruckkrkh. 28, 377-378 (1999).
56. Schulz W., H. Holler, G. Delling: Bone markers, bone mineral density and histology in chronic dialysis patients with adynamic bone disease. 30. Nephrologischcs Seminar Bamberg, 30.06 01.07.2006, Abstract-Band, Seite 60 (2006).
57. Schulz W., J. Roth, K. Famira, G. Delling: Therapie der histologisch gesicherten rcnalen Osteopenie mit Parathormon (PTH-Fragment 1-34, Teriparatid, Forsteo®) (2 Kasuistiken). 30. Nephrologisches Seminar Bamberg, 30.06 - 01.07.2006, Abstract-Band, Seite 61-64 (2006).
58. Sherrard D.J., G. Hercz, Y. Pei, N.A. Moloney, C. Greenwood, A. Manuel, C. Saiphoo, S.S. Fenton, D.J. Sherrard: The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int. 43, 436-442 (1993).
59. Slinin Y., R.N. Folin, A.J. Collins: Calcium, phosphorus, parathyroid hormone and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3 and 4 study. J. Am. Soc. Nephrol. 16, 1788-1793 (2005).
60. Stevens L.A., O. Djurdjev, S. Cardew, E.C. Cameron, A. Levin: Calcium, phosphate and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J. Am. Soc. Nephrol. 15, 770-779 (2004).
61. (3) analogue administration in dialysis patients with end-stage renal disease. Nephron 84, 13-20 (2000).
62. Young E.W., S. Satayathum, R. Pisoni, F. Locatelli, B. Canaud, K. Kurokawa, T. Akiba, A. Saito, D. Mapes, F. Port: Prevalence of values on mineral metabolism being outside the targets from the proposed draft NKF-K/DOQI and European best practice guidelines in countries of the dialysis outcomes and practice patterns study (DOPPS). Nephrol. Dial. Transplant. 18 (Suppl. 4), A677 (Abstract W414) (2003).
63. Young E.W., J.M. Albert, S. Satayathum, D.A. Goodkin, R.L. Pisoni, T. Akiba et al.: Predictors and consequences of altered mineral metabolism: The Dialysis Outcome Practice Patterns Study. Kidney Int. 67, 1179-1187 (2005).